CSPC Pharmaceutical Group (HKG:1093) expects a 26% year-over-year decline in attributable profit for the year 2024 from around 5.87 billion yuan a year prior, a Tuesday filing with the Hong Kong bourse said.

The pharmaceutical firm attributed the lower anticipated profit mainly to a decrease in revenue of the finished drugs business.

Shares of the company were down nearly 4% in recent trade.